S100P and neoplasm: While other RAGE inhibitors, such as cromolyn and a S100P-derived inhibitor, have shown anti-tumor effects in pancreatic cancer models, their mechanisms are often limited to binding specifically to S100P, which restricts their utility against other RAGE ligands involved in pancreatic cancer progression [15,32,33].